SG Americas Securities LLC Boosts Stake in Bausch Health Companies Inc. (NYSE:BHC)

SG Americas Securities LLC boosted its position in Bausch Health Companies Inc. (NYSE:BHC - Free Report) by 62.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,301,981 shares of the company's stock after acquiring an additional 1,263,706 shares during the quarter. SG Americas Securities LLC owned 0.91% of Bausch Health Companies worth $26,614,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of BHC. Merit Financial Group LLC bought a new position in shares of Bausch Health Companies in the 4th quarter valued at $228,000. Sanders Morris Harris LLC lifted its stake in shares of Bausch Health Companies by 16.0% in the fourth quarter. Sanders Morris Harris LLC now owns 28,975 shares of the company's stock worth $234,000 after acquiring an additional 4,000 shares during the period. Range Financial Group LLC bought a new stake in shares of Bausch Health Companies in the 4th quarter valued at $1,004,000. Geode Capital Management LLC boosted its position in Bausch Health Companies by 20.5% during the third quarter. Geode Capital Management LLC now owns 636,082 shares of the company's stock valued at $6,448,000 after acquiring an additional 108,269 shares during the last quarter. Finally, XTX Topco Ltd acquired a new stake in Bausch Health Companies during the third quarter worth approximately $938,000. Institutional investors and hedge funds own 78.65% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the stock. Royal Bank of Canada raised their price target on shares of Bausch Health Companies from $10.00 to $11.00 and gave the stock a "sector perform" rating in a report on Friday, November 1st. Evercore ISI upgraded Bausch Health Companies to a "hold" rating in a research note on Tuesday, October 15th. Finally, StockNews.com raised Bausch Health Companies from a "hold" rating to a "buy" rating in a report on Friday, October 25th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and two have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $7.75.

Bausch Health Companies Trading Up 1.2 %

Shares of BHC stock traded up $0.10 during trading on Thursday, reaching $7.82. 1,568,070 shares of the company's stock traded hands, compared to its average volume of 3,642,190. The firm's 50-day moving average is $7.84 and its 200 day moving average is $7.45. The company has a market capitalization of $2.83 billion, a P/E ratio of -16.28 and a beta of 0.69. Bausch Health Companies Inc. has a 1 year low of $3.96 and a 1 year high of $11.46.

Bausch Health Companies (NYSE:BHC - Get Free Report) last announced its quarterly earnings results on Wednesday, October 30th. The company reported $1.12 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.10. Bausch Health Companies had a negative return on equity of 755.86% and a negative net margin of 1.88%. The company had revenue of $2.51 billion during the quarter, compared to analysts' expectations of $2.42 billion. During the same period in the previous year, the business earned $1.03 earnings per share. The firm's quarterly revenue was up 12.2% compared to the same quarter last year. As a group, sell-side analysts predict that Bausch Health Companies Inc. will post 3.73 earnings per share for the current fiscal year.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.